Biotech in Asia: looking forward to 2023
Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights…
Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights…
Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement…
Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical…
Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial…
Astellas Pharma Inc. has announced positive topline results from its phase 3 SPOTLIGHT clinical trial…
Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement…
A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European…
Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and…
Astellas Pharma Inc. has announced topline results from its phase 3 MOONLIGHT 3 clinical trial…
Astellas Pharma Inc. has unveiled plans to create an integrated biotechnology campus in South San…
Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a…
Japanese pharma giant Astellas has acquired the UK biotech Nanna Therapeutics for up to €80M…